A probable interaction between warfarin and the antiretroviral TRIO study regimen

Annals of Pharmacotherapy

Volumn 46, Issue 11, 2012, Pages

  Liedtke, Michelle D ^a   Vanguri, Amulya ^b   Chris Rath, R ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

Author keywords

Antiretroviral; Darunavir; Drug interaction; Etravirine; HIV; Integrase strand transfer inhibitor; Nonnucleoside reverse transcriptase inhibitor; Protease inhibitor; Raltegravir; Warfarin

Indexed keywords

AZITHROMYCIN; BUSPIRONE; DAPSONE; DARUNAVIR; EMTRICITABINE; ETRAVIRINE; FLUCONAZOLE; FLUDROCORTISONE; HYDROCODONE; LISINOPRIL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; POTASSIUM CHLORIDE; PREDNISONE; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VALGANCICLOVIR; WARFARIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG INTERACTION; DRUG METABOLISM; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL NORMALIZED RATIO; MONOTHERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; TRANSSEXUALISM; TREATMENT DURATION; VIRUS LOAD;

ANTICOAGULANTS; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MIDDLE AGED; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; SULFONAMIDES; VENOUS THROMBOSIS; WARFARIN;

EID: 84869222688     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R290     Document Type: Article

References (11)

1. Darin KM, Esterly JS, Gerzenshtein L, Postelnick MJ, Scarsi KK. The clinical implications of antiretroviral drug interactions with warfarin: a case-control study (abstract P_18). Rev Antivir Ther Infect Dis 2012;3:42-3.
2. Rathbun RC, Liedtke MD. Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management. Pharmaceutics 2011;3: 745-81.doi: 10.3390/pharmaceutics3040745
3. Liedtke MD, Rathbun RC. Drug interactions with antiretrovirals and warfarin. Expert Opin Drug Saf 2010;9:215-23.doi: 10.1517/14740330903493458
4. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multi-drug resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009;49:1441-9.doi: 10.1086/630210
5. Horn JR, Hansten PD, Chan L-N. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674-80.doi: 10.1345/aph.1H423
6. Sekar V, Spinosa-Guzman S, Meyvisch P, et al. Cocktail study to investigate the in-vivo drug interaction potential of darunavir coadministered with low-dose ritonavir (DRV/r; RTV) on cytochrome P450 enzymes 2D6, 2C9 and 2C19 (abstract P23). 9th International Workshop on Clinical Pharmacology of HIV (IWCPHIV), New Orleans, LA, April 7-9, 2008.
7. European Medicines Agency. CHMP assessment report for intelence. 2008. http://www.emea.europa.eu/humandocs/PDFs/EPAR/intelence/H-900-en6.pdf (accessed 2010 Mar 1).
8. Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35:1657-63.doi: 10.1124/dmd.107.016196
9. Crussell-Porter LL, Rindone JP, Ford MA, Jaskar DW. Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium. Arch Intern Med 1993;153:102-4.doi: 10.1001/archinte.1993.00410010124012
10. Truong T, Haley J. Probable warfarin and dapsone interaction. Clin Appl Thromb Hemost 2012;18:107-9.doi: 10.1177/1076029611418963
11. Hazlewood KA, Fugate SE, Harrison DL. Effect of oral corticosteroids on chronic warfarin therapy. Ann Pharmacother 2006;40:2101-6.doi: 10.1345/aph.1H418